Navigation Links
IPM Receives Worldwide Rights to HIV Prevention Medicine
Date:5/8/2014

Silver Spring, MD (May 8, 2014) — The International Partnership for Microbicides (IPM) announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement expands on IPM's existing rights to develop, manufacture and commercialize dapivirine-based products for use by women in developing countries and will now give women in developed countries access to products containing dapivirine, such as a vaginal ring that combines dapivirine and a contraceptive.

A future market for a contraceptive-dapivirine ring in developed countries could help fund IPM's nonprofit mission to develop HIV and multipurpose prevention technologies (MPTs) for women in resource-poor countries, among whom HIV has taken its highest toll. This sustainable funding stream would help ensure that the most at-risk women around the world have affordable access to new prevention technologies in the future.

"Women are in a race against time for new HIV prevention methods, and they need innovative tools to protect themselves and help reverse the course of the epidemic," said Dr. Zeda F. Rosenberg, chief executive officer of IPM. "We applaud Janssen's leadership in advancing women's access to new health technologies."

Janssen has been an essential partner in IPM's work, and today's announcement with Janssen's newly-established Global Public Health group marks the next step in this longstanding collaboration. Janssen originally licensed dapivirine to IPM under a royalty-free agreement in 2004 to develop the antiretroviral (ARV) medicine as a microbicide for women in resource-poor countries. The expanded worldwide rights are an affirmation of this partnership and dapivirine's potential. IPM, a nonprofit product developer, can develop and commercialize dapivirine in combination with contraceptives and other ARVs. Through the worldwide rights agreement with Janssen, IPM has opened the door to women's future access to prevention products in all countries through affordable pricing strategies.

IPM's most advanced technology containing dapivirine is a monthly sustained-release vaginal ring designed to prevent HIV. The dapivirine-only microbicide ring is now in two parallel Phase III trials in Africa, with results expected in late 2015. Building on Janssen's earlier work with dapivirine, IPM designed and developed the ring, conducting all the preclinical and clinical work needed to bring the product to late-stage efficacy trials in just seven years. A successful microbicide would be a key tool in helping to reduce new HIV infections in developing countries in the future.

"Our worldwide rights agreement with Janssen is a powerful example of how public-private partnerships can accelerate access to urgently needed, affordable health products," added Dr. Rosenberg. "By pooling the expertise of partners across sectors, we can more effectively help women at risk for HIV and, ultimately, end the spread of HIV/AIDS altogether."

Dapivirine belongs to a class of ARVs called non-nucleoside reverse transcriptase inhibitors (NNRTIs) that prevent HIV from making copies of itself. Other dapivirine-based products in IPM's development portfolio include a combination dapivirine-maraviroc ring, as well as a 90-day MPT ring that combines dapivirine with the contraceptive levonogestrel for dual protection against HIV and unintended pregnancy. IPM's long-acting MPT ring is now in preclinical studies under a grant from USAID, with a clinical trial planned for 2015.

"This agreement could have profound implications for women's health," said Dr. Peter Piot, director of the London School of Hygiene & Tropical Medicine and founding executive director of UNAIDS. "Not only will it expand women's access to affordable, potentially lifesaving prevention products but also make sure research into new tools continues. It serves as a valuable model for how creative partnerships can help tackle some of the most daunting global health challenges."

HIV/AIDS is among the greatest obstacles to women's health and development. Although the last decade has witnessed remarkable achievements against the epidemic — with new infections down by one-third since 2001 — this progress has largely left women behind. In some parts of sub-Saharan Africa, women ages 15 to 24 are three to four times more likely to be infected with HIV as men in the same age group. Women-initiated tools, including microbicides and MPTs in the form of vaginal rings, films and gels, are being developed because the best weapon against HIV is a range of unique options that give women protection that meets their needs.

Since 2004, five major pharmaceutical companies — Bristol-Myers Squibb, Gilead, Merck & Co., ViiV Healthcare and Janssen — have entered into royalty-free licenses with IPM to develop, manufacture and distribute eight ARV products as microbicides in developing countries. These licenses ensure that any new product will be provided at low cost in the settings where these new tools are most urgently needed.

IPM's work is made possible through the generous support of the Ministry of Foreign Affairs of Denmark, Irish Aid, the Ministry of Foreign Affairs of the Netherlands, the Norwegian Agency for Development Cooperation (Norad), the United Kingdom Department for International Development (DFID), the American people through the United States Agency for International Development (USAID), the Bill and Melinda Gates Foundation, the M.A.C. AIDS Fund and the OPEC Fund for International Development.

###
About IPM: IPM is a nonprofit organization dedicated to developing new HIV prevention tools and other sexual and reproductive health technologies for women, and making them available in developing countries. IPM has offices in the United States and South Africa. Please visit http://www.IPMglobal.org.

Contacts:

IPM US and Europe: Holly Seltzer, hseltzer@IPMglobal.org">hseltzer@IPMglobal.org, +1.301.608.4277

IPM Africa: Leonard Solai, lsolai@IPMglobal.org">lsolai@IPMglobal.org, +27.21.860.2314


'/>"/>
Contact: Holly Seltzer
hseltzer@ipmglobal.org
301-608-4277
International Partnership for Microbicides (IPM)
Source:Eurekalert

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The narrative ... offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the ... disorder and his attempts to overcome them. , Schanssema, initially unsure of the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The International Association ... annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected from ... be showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 ...
(Date:2/24/2017)... ... ... The Radiology Business Management Association will select the 2017 Quest ... Better Radiology Marketing Programs conference, held this year from March 5 to 7 ... given out in five categories. They are:, ,     Patient Marketing, a ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... qualifying into the Senior International Elite division on February 12th. Ms. Esparza ... divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida is ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the Cowen and Company 37 th ... Copley Place on Tuesday, March 7, 2017 at 11:20 ... of the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Hemophilia market? What are the unit prices and annual ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
Breaking Medicine Technology: